PTC-028

• Description :

  PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. PTC-028 downregulates BMI-1, inducing caspase-mediated apoptosis[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; BMI1

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Stem Cell/Wnt

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ptc-028.html

• Purity :

  98.0

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  FC(C1=CC=C(NC2=NC(N3C4=CC(F)=C(F)C=C4N=C3C)=CN=C2)C=C1)(F)F

• Molecular Formula :

  C19H12F5N5

• Molecular Weight :

  405.32

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Dey A, et al. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 Jan;17 (1) :39-49.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1782970-28-8]